FLGT logo

FULGENT GENETICS INC

FLGTNASDAQ
πŸ† #2562 by market capEarnings Feb 26US Equity
β€”β€”
Quote unavailable
πŸ””
Track FLGT
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$674M
Small Cap
πŸ“ˆRevenue Growth (YoY)
6.8%
Slowing
πŸ“ŠGross Margin
35.6%
Healthy
πŸ’΅FCF Margin
2.1%
Thin
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for FLGT.

Trading Snapshot

Day Range
β€”
52-Week Range
$13.46 – $31.04
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
27.5M
Next Earnings
2027-02-26

Fundamentals Snapshot

Annual Revenue
$323M
Last Q Revenue
$90M
P/E Ratio
β€”
P/S Ratio
2.1x
EPS (TTM)
$-2.83
Dividend Yield
β€”
Dilution (1yr)
+0.4%
FLGT logo

FULGENT GENETICS INC

FLGT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$323Mβ–² +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
40.6%β–² +7.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$91Mβ–² +23.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$124Mβ–² +545.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.8Mβ–² +0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$43Mβ–Ό βˆ’$4M YoY
StockOtter Β· stockotter.space

About FULGENT GENETICS INC

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Nov 2026

Latest News & Updates

Zacks Investment ResearchΒ·4d ago

Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could l

Fool - Investing NewsΒ·4d ago

Fulgent: 3 Key Takeaways for Long-Term Investors

Billing software fixes are lifting collection rates, but the reimbursement framework behind them remains a variable investors must weigh.

Seeking AlphaΒ·16d ago

Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript

Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conferenc

MarketBeatΒ·16d ago

What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call

Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company rea

Zacks Investment ResearchΒ·17d ago

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.

Business WireΒ·17d ago

Fulgent Reports Third Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (β€œFulgent,” or the β€œCompany”), a technology-based company with a well-established laboratory services business and a therapeutic development busine